## Initial Workup

- A thorough history and physical examination
- Routine laboratory tests to assess:
  - Iron deficiency anemia.
  - Liver and kidney functions.
- Upper GI endoscopy and adequate biopsy: to provide tissue diagnosis and molecular biomarkers.
- Laparoscopy in M0 cases planned for definitive treatment (surgery or concurrent chemoradiotherapy) to evaluate for peritoneal spread. N.B. Laparoscopy is not indicated if palliative treatment is planned.
- Radiological Assessment:
  - Computerized Tomography (CT) thorax + abdomen ± pelvis for clinical staging.
  - Endoscopic Ultrasound (EUS) for accurate assessment of T and N stage in potentially operable tumors. It determines the proximal and distal extent of tumors.
  - A positron emission tomography (PET) scan [for occult metastasis]: PET scan is optional if available. Considered if the result would change the treatment plan. It could be false negative in mucinous and diffuse adenocarcinomas.

---

**Tumors arising at the esophagogastric junction (EGJ) or in the cardia of the stomach within 5 cm of the EGJ that extend into the EGJ or esophagus are staged and treated as esophageal rather than stomach cancers.**

**Tumors that arise beyond 5 cm of the EGJ or are within 5 cm of the EGJ but without extension to the esophagus or EGJ are classified and treated as gastric cancers.**

*The 8th edition of the TNM staging manual*
SUMMARY OF PREFERRED SYSTEMIC CHEMOTHERAPY REGIMENS FOR LOCALIZED DISEASE

LOCALIZED DISEASE

- Perioperative chemotherapy or postoperative chemoradiotherapy for localized gastric cancer (6)
- Postoperative chemotherapy following D2 lymph node dissection
- 5FU and Capecitabine can be used interchangeably except as indicated.
- Cisplatin and Oxaliplatin can be used interchangeably except as indicated
SUMMARY OF PREFERRED SYSTEMIC CHEMOTHERAPY REGIMENS FOR ADVANCED DISEASE (FIRST-LINE)

ADVANCED DISEASE

First-Line

HER2 Positive

5FU and Cisplatin combination

Trastuzumab with Chemotherapy (not recommended with anthracyclines)

HER2 Negative

Preferred Regimen

5FU (or Capecitabine) + Cisplatin (or Oxaliplatin)

Other Regimens

- ECF and ECF modifications
- DCF and DCF modifications
- Paclitaxel or Docetaxel single agents
- Paclitaxel or Docetaxel with cisplatin
- 5FU or Capecitabine single agent
- 5FU and Irinotecan
SUMMARY OF PREFERRED SYSTEMIC CHEMOTHERAPY REGIMENS FOR ADVANCED DISEASE (SECOND-LINE)

ADVANCED DISEASE

Second-Line

Preferred Regimen

Ramucirumab + Paclitaxel

Taxanes single agent either Paclitaxel or Docetaxel

Irinotecan

5FU + Irinotecan

Other Regimens

Ramucirumab monotherapy

Irinotecan doublet with (cisplatin or with Docetaxel).

Nivolumab (after ≥ 2 prior therapies)

TAS-102 (after ≥ 2 prior therapies)

Pembrolizumab in pretreated disease (with dMMR, MSI-H, or overexpression of PD-L1)
# Principles of Systemic Treatment for Resectable or Localized EGJ/Gastric Cancer

## Perioperative Chemotherapy<sup>(1-4)</sup>: Inclusive of GE Junction Adenocarcinoma

**Preferred regimens:**
- Two-drug regimen: 5-Fluorouracil (5FU) + Oxaliplatin
- Three-drug regimen: FLOT (5-FU/Leucovorin, Oxaliplatin and Docetaxel) (category 1)

Due to toxicity, the three-drug regimen is recommended only for medically fit patients.

**Other regimens:**
- 5FU + Cisplatin

## Postoperative Chemoradiation<sup>(5)</sup>: Inclusive of GE Junction Adenocarcinoma

Fluoropyrimidine (infusional fluorouracil or capecitabine) before and after Fluoropyrimidine-based chemoradiation.

## Preoperative Chemoradiation<sup>(7)</sup>: For GE Junction and Gastric Cardia Tumours

**Preferred regimens:** (category 1)
- Paclitaxel + Carboplatin
- 5FU (or Capecitabine) + Oxaliplatin (or Cisplatin)

**Other regimens:** (category 2B)
- Paclitaxel + 5FU (or Capecitabine)

## Postoperative Chemotherapy<sup>(6)</sup>: For Patients who have undergone primary D2 Lymph Node Dissection

Capecitabine + Oxaliplatin (category 1).
I. Perioperative chemotherapy for medically fit cT2 or higher any N (Category 1)

<table>
<thead>
<tr>
<th>Regimen</th>
<th>Dose</th>
<th>Supporting Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Perioperative (ECF) or ECF modified based therapy: • Epirubicin, • Cisplatin and • Infused 5-fluorouracil</td>
<td>This approach includes: • 3 preoperative cycles and • 3 postoperative cycles</td>
<td>The adoption of this perioperative chemotherapy approach for the treatment of gastric cancer was a result of the MAGIC and the French FNLCC/FFCD trials (^1-^3).</td>
</tr>
<tr>
<td>Perioperative FLOT based therapy [Standard of Care]: • 5-fluorouracil, • Leucovorin, • Docetaxel, and • Oxaliplatin</td>
<td>This approach includes: • 4 preoperative cycles and • 4 postoperative cycles</td>
<td>The results from the more recent Phase III FLOT4-AIO trial showed significant superiority of perioperative 5-fluorouracil, leucovorin, docetaxel, and oxaliplatin (FLOT) compared with ECF (^4).</td>
</tr>
</tbody>
</table>

II. Post-operative management for patients who have not received pre-operative chemotherapy or chemoradiotherapy.

a. Postoperative Chemoradiotherapy (category 1)

<table>
<thead>
<tr>
<th>Regimen</th>
<th>Indication</th>
<th>Supporting Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>This approach includes: Fluoropyrimidine: • Infusional 5-FU or • Capecitabine before and after concomitant fluoropyrimidine-based chemoradiation (^5).</td>
<td>It is considered the standard approach for completely resected gastric cancer.</td>
<td>It is adapted from the INT0116 study.</td>
</tr>
</tbody>
</table>

b. Postoperative Chemotherapy (category 1)

<table>
<thead>
<tr>
<th>Regimen</th>
<th>Indication</th>
<th>Supporting Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adjuvant therapy: Postoperative chemotherapy (XELOX).</td>
<td>It is recommended following D2 lymph node dissection.</td>
<td>It is supported by the multicenter CLASSIC trial.</td>
</tr>
</tbody>
</table>
Principles of Systemic Therapy for Locally Advanced Unresectable Non-Metastatic Disease

- The role of induction therapy in those patients is unclear.
- These cases should be discussed in a multidisciplinary team setting.
- The reasonable approach is an initial attempt at down-staging with:
  - Chemotherapy using regimens for metastatic disease,
  - Chemoradiotherapy, or
  - A combination followed by careful restaging and surgical exploration in responders who have no evidence of metastatic disease.

Principles of Systemic Therapy for Metastatic Disease

I. Role of Systemic Chemotherapy

**Preferred Regimens:**

- Two-drug cytotoxic regimen
  - [preferred for patients with advanced disease because of lower toxicity]
- Three-drug cytotoxic regimen
  - [reserved for medically fit patients with good performance status and access to frequent toxicity evaluation]

- Choice of therapy is based on:
  - Performance status (PS)
  - Practice preference
  - Comorbidities
  - Toxicity profile
  - Possible contraindications
  - Availability of the agents

II. Role of Targeted Therapy (Anti-HER2)

**Preferred Regimens:**

- Trastuzumab (Herceptin) + Chemotherapy (except anthracyclines)

The addition of the human epidermal growth factor receptor 2 (HER2)-targeted therapy trastuzumab (Herceptin) to chemotherapy in the first-line setting has shown a survival benefit for patients with HER2-positive advanced gastric or GEJ cancer, with a median overall survival (OS) of 13.8 months versus 11.1 months with chemotherapy alone. Trastuzumab is not recommended for use with anthracyclines.

III. Role of Targeted Therapy (Angiogenesis Inhibition)

**Preferred regimens:**

- Ramucirumab + Paclitaxel
Ramucirumab showed benefit in the second line in both the RAINBOW and REGARD trials. In RAINBOW, ramucirumab was assessed in combination with paclitaxel. The OS was 9.6 months for ramucirumab plus paclitaxel versus 7.4 months for placebo plus paclitaxel. REGARD study showed a survival benefit with ramucirumab monotherapy, but it was more modest than with the ramucirumab and paclitaxel combination in the RAINBOW study\(^9,10\).

IV. Other Chemotherapy Compounds

**Preferred Regimens:**

- Trifluridine/Tipiracil (TAS-102; FTD/TPI; Lonsurf)

In the phase III TAGS trial, trifluridine/tipiracil (TAS-102; FTD/TPI; Lonsurf) reduced the risk of death by about one-third compared with placebo in patients with heavily pretreated gastric or GEJ cancer\(^11\).

V. Role of Immunotherapy

Data is emerging regarding the role and timing of immunotherapy in the treatment landscape of advanced gastroesophageal cancers\(^12\text{-}14\).

a) Pembrolizumab:

**Suggested Regimens:**

- **Pembrolizumab** in advanced disease (with dMMR, Microsatellite instability-high (MSI-H), or overexpression of the programmed cell death ligand 1 (PD-L1)) and progressing on standard therapy [previously treated with two or more lines of chemotherapy] with no satisfactory alternative option available.

Based on the results of the phase II KEYNOTE-059 study, the FDA approved the anti–PD-1 immunotherapy pembrolizumab (Keytruda) for PD-L1–positive recurrent or advanced gastric or GEJ adenocarcinomas previously treated with two or more lines of chemotherapy.

In phase III KEYNOTE-061 study, Shitara et al., compared pembrolizumab with paclitaxel in patients with advanced gastric or GEJ cancer that progressed on first-line therapy with platinum and fluoropyrimidine and found that it was not as favorable.\(^16\) The median OS was 9.1 months with pembrolizumab versus 8.3 months with paclitaxel.

KEYNOTE-061 also included PD-L1–negative patients with advanced gastric or GEJ cancer, and a post hoc analysis showed benefit with increased PD-L1 expression. A higher PD-L1 expression showed a higher benefit [with pembrolizumab], with a hazard ratio of 0.64 compared with paclitaxel [in patients with a PD-L1 combined positive score (CPS) of ≥10]. The treatment with pembrolizumab also improved OS in patients with a CPS ≥5, with an HR of 0.73.

The hypothesis that MSI-H/dMMR tumors might be particularly susceptible to immune checkpoint inhibition with PD-1 inhibitors was addressed in a proof of concept study in which 86 patients including
advanced gastroesophageal cancer, whose tumors were dMMR were treated with pembrolizumab. Objective radiographic responses were observed in 53% of patients, and 21% had complete responses. Pembrolizumab may represent a treatment option for patients who have advanced disease (with dMMR, MSI-H, or overexpression of the programmed cell death ligand 1 (PD-L1)) and progressing on standard therapy with no satisfactory alternative option available

b) Nivolumab:

**Suggested regimens:**
- **Nivolumab** in the advanced disease who had failed two or more standard chemotherapy regimens.

The ATTRACTION-2 trial is a phase 3 trial that evaluated the role of nivolumab in Asian patients with advanced gastric or EGJ cancer who had failed two or more standard chemotherapy regimens. The objective response rate with nivolumab was 11 percent, and median overall survival was improved compared with placebo (5.3 versus 4.1 months [HR 0.63, 95% CI 0.51-0.78], 12-month survival 27 versus 11 percent); median PFS was also improved (1.61 versus 1.45 months [HR 0.60 95% CI 0.49-0.75]). A comparable degree of benefit in Western populations was suggested in the phase II trial CheckMate 032. Therapy with nivolumab was not restricted to patients expressing a PD-L1 or dMMR/MSI-H tumors

---

### PREFERRED SYSTEMIC CHEMOTHERAPY REGIMENS FOR ADVANCED DISEASE

#### FIRST-LINE THERAPY

**HER2 Positive Disease:**
- Trastuzumab should be added to first-line chemotherapy for HER2 overexpressing advanced disease
- Trastuzumab combination with 5FU and cisplatin (category 1).
- Trastuzumab is not recommended for use with anthracyclines.

**HER2 Negative Disease:**
- 5FU (or Capecitabine) + Cisplatin (or Oxaliplatin) (category 1).

**Other Regimens:**
- ECF and ECF modifications
- DCF and DCF modifications
- Paclitaxel or Docetaxel single agents
- Paclitaxel or Docetaxel with cisplatin
- 5FU or Capecitabine single agent
- 5FU and irinotecan
SECOND-LINE OR SUBSEQUENT THERAPY:

Dependent on prior therapy and performance status patient maybe (9-12, 15-18, 39-44)

Preferred Regimens:

- Ramucirumab + Paclitaxel (category 1).
- Taxanes single agent, either Paclitaxel or Docetaxel (category 1).
- Irinotecan (category 1).
- 5FU + Irinotecan (category 1).

Other Regimens:

- Ramucirumab monotherapy (category 1).
- Irinotecan doublet with (cisplatin or wit Docetaxel).
- Nivolumab (after ≥ 2 prior therapies).
- TAS-102 (after ≥ 2 prior therapies and depending on availability).
- Pembrolizumab may represent an option for the pretreated disease [with dMMR, MSI-H, or overexpression of the programmed cell death ligand 1 (PD-L1).

Further Considerations in the Palliative Approach for Advanced Disease

- **Obstruction:** Stent, laser, radiotherapy (RT), or surgery
- **Pain:** Medication ± RT
- **Bleeding:** RT, surgery, endoscopic therapy
- **Nutritional support**

Post-Treatment Cancer Surveillance

There are no randomized trials to guide the postoperative surveillance strategy. Consensus-based guidelines from the National Comprehensive Cancer Network (NCCN) suggests the following:

- **History and physical examination:** Every three to six months for 1 – 3 years, then Every six months for years 4 and 5, then As clinically indicated afterward
- **CBC and chemistry profile:** As clinically indicated
- **Radiologic imaging or endoscopy:** As clinically indicated
- **Nutritional deficiency in surgically treated patients:** Monitor and treat as indicated

**Hereditary diffuse gastric cancer:**

Prophylactic total gastrectomy is recommended between ages 18 and 40 for CDH1 mutation carriers.

**Lynch syndrome (LS):**

Selected individuals or families or those of Asian descent may consider esophagogastroduodenoscopy (EGD) with extended duodenoscopy.
References


